Inotersen sodium is a Antisense Oligonucleotide owned by Akcea Therapeutics, and is involved in 9 clinical trials, of which 5 were completed, and 4 are ongoing.

ISIS-TTRRx is a transthyretin (TTR) protein inhibitor. Normal and mutant forms of TTR progressively accumulate in tissues in transthyretin amyloidosis hence impairing the tissue function. The drug candidate blocks the production of both normal and mutant TTR due to which the supply of TTR protein is reduced, which leads to the prevention of the formation of TTR amyloid deposits in the tissues.

The revenue for Inotersen sodium is expected to reach a total of $877m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Inotersen sodium NPV Report.

Inotersen sodium was originated by Ionis Pharmaceuticals and is currently owned by Akcea Therapeutics. PTC Therapeutics, Ionis Pharmaceuticals and Swedish Orphan Biovitrum are the other companies associated in development or marketing of Inotersen sodium.

Inotersen sodium Overview

Inotersen sodium (Tegsedi) is a methoxyethyl phosphorothioate antisense oligonucleotide. It is formulated as solution for subcutaneous route of administration. Tegsedi is indicated for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR) and also indicated for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin-associated amyloidosis (PAF-TTR) to slow disease progression and improve quality of life

It is under development for the treatment of amyloid cardiomyopathy and familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis). It is administered through subcutaneous route. It was under development for familial amyloid neuropathies.

Ionis Pharmaceuticals Overview

Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.

The company reported revenues of (US Dollars) US$810.5 million for the fiscal year ended December 2021 (FY2021), an increase of 11.1% over FY2020. The operating loss of the company was US$38.8 million in FY2021, compared to an operating loss of US$172.1 million in FY2020. The net loss of the company was US$28.6 million in FY2021, compared to a net loss of US$444.3 million in FY2020. The company reported revenues of US$159.8 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.

Quick View – Inotersen sodium

Report Segments
  • Innovator (NME)
Drug Name
  • Inotersen sodium
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.